

PRN, the Newsletter for Community Pharmacists presents:

Comparison of 3 Leading COVID-19 Coronavirus Vaccine Candidates			
Maker	Pfizer-BioNTech	Moderna	AstraZeneca/Oxford
Name	BNT162b2	mRNA-1273	AZD1222
Type	Nucleoside-modified mRNA vaccine formulated with lipid nanoparticles	Nucleoside-modified mRNA vaccine formulated with lipid nanoparticles	Modified chimpanzee adenovirus vector DNA vaccine
Efficacy	Primary efficacy data: 95% effective against COVID-19 beginning 28 days after first dose. 162 confirmed infections in placebo group vs. 8 in vaccine group.	Primary efficacy data: 94.1% effective against COVID-19 beginning 14 days after second dose. 185 confirmed infections in placebo group vs. 11 in vaccine group.	Interim efficacy data: 70% effective against COVID-19. This overall figure combines results of two different dosing regimens: two standard doses = 62% effective; low dose followed by standard dose = 90% effective.
Dosage and Administration	2 doses of 0.3 mL given 21 days apart. Thaw prior to use and dilute multidose vial with 1.8 mL of supplied saline diluent. Invert gently 10 times. Vial supplies 5 doses of vaccine, which must be used within 6 hours of reconstitution.	2 doses of 0.5 mL given 28 days apart Thaw prior to use and swirl gently before withdrawing dose. No dilution required. Vial supplies 10 doses of vaccine.	2 doses of 0.5 mL given 28 days apart. No dilution required. Vial supplies 10 doses of vaccine, which must be used within 4 hours of first needle puncture.
Storage	Frozen Can be stored for up to 6 months at -70°C (-94°F) Can be stored for up to 5 days at 2° to 8°C (36° to 46°F) Undiluted vial stable for 2 hours at room temperature	Frozen Can be stored for up to 6 months at -20°C (-4°F) Can be stored for up to 30 days at 2° to 8°C (36° to 46°F) Intact vial stable for 12 hours at room temperature	Refrigerated Can be stored at 2° to 8°C (36° to 46°F) until expiration date printed on packaging